SummaryCephalexin, also known as KEFLEX®, is a semisynthetic cephalosporin antibacterial drug that works by inhibiting PBPs. It was first approved in 1971 in the US by Pragma Pharmaceuticals LLC for oral administration. Cephalexin is used to treat various bacterial infections such as respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections. Its molecular formula is C16H17N3O4S•H2O with a molecular weight of 365.41. KEFLEX® capsules are intended for oral administration and contain 7-(D-α-Amino-α-phenylacetamido)-3-methyl-3-cephem-4-carboxylic acid monohydrate. |
Drug Type Small molecule drug |
Synonyms Ammonia benzyl cephalosporin, Cafalexin, Cefaiexin + [24] |
Target |
Action inhibitors |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (04 Jan 1971), |
Regulation- |
Molecular FormulaC16H19N3O5S |
InChIKeyAVGYWQBCYZHHPN-CYJZLJNKSA-N |
CAS Registry23325-78-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00906 | Cephalexin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute bacterial sinusitis | Australia | 24 Feb 2004 | |
Acute prostatitis | Australia | 24 Feb 2004 | |
Bacterial otitis media | Australia | 24 Feb 2004 | |
Beta-hemolytic Streptococcus infection | Australia | 24 Feb 2004 | |
Complicated skin and soft tissue infection | Australia | 24 Feb 2004 | |
Pneumococcal Infections | Australia | 24 Feb 2004 | |
Bacterial Infections | China | 01 Jan 1981 | |
Cystitis | Japan | 01 Aug 1978 | |
Pneumonia | Japan | 01 Aug 1978 | |
Acute Bronchitis | Japan | 14 Apr 1972 | |
Complicated skin and skin structure infection | Japan | 14 Apr 1972 | |
Dacryocystitis | Japan | 14 Apr 1972 | |
Hordeolum | Japan | 14 Apr 1972 | |
Jaw inflammation | Japan | 14 Apr 1972 | |
Keratitis | Japan | 14 Apr 1972 | |
Lymphadenitis | Japan | 14 Apr 1972 | |
Lymphangitis | Japan | 14 Apr 1972 | |
Mastitis | Japan | 14 Apr 1972 | |
Maxillary Sinusitis | Japan | 14 Apr 1972 | |
Myositis | Japan | 14 Apr 1972 |
Not Applicable | - | nzfwyhigfs(jepwwgzvox) = xyahqojbbv zsrxdovrce (zccjagehii ) | - | 23 Feb 2024 | |||
nzfwyhigfs(jepwwgzvox) = mmobprpvat zsrxdovrce (zccjagehii ) | |||||||
Phase 3 | 98 | (Antibiotics for a 24 Hour Period) | ivnnmaqmwf = tykdoffmvx hbhctnnfqr (hgaklcqdxy, yqqduuikyw - btybboeinc) View more | - | 14 Mar 2023 | ||
(Continued Antibiotics) | ivnnmaqmwf = kqbxxspewx hbhctnnfqr (hgaklcqdxy, gkacryrqnc - uqhljlxflv) View more | ||||||
Not Applicable | 220 | Cephalosporins (Direct GOC challenge) | qjfldaxqoi(wnkmywisnh) = aramrjhnwq dumvmlgevt (zifklgzsrr ) View more | - | 01 Feb 2023 | ||
Not Applicable | - | pifobobmkf(wkpzildpmv) = riwjhacgot eknnqxsyzc (eskplmbqmw ) | - | 01 Feb 2023 | |||
Phase 4 | 69 | High-dose cephalexin (1000 mg) | xkatbqsagf(ixdqukbfnd) = syxusjtwsi eukpssduth (pspzlwumzi, 43.1 - 59.8) | - | 02 Jan 2023 | ||
Phase 3 | - | nimycjjklc(eugjprbwqr) = jgqlekexsa uvqcenchwi (qnwurcbmym ) View more | Positive | 05 Dec 2022 | |||
Cephalexin and placebo | nimycjjklc(eugjprbwqr) = crxasbogqc uvqcenchwi (qnwurcbmym ) View more | ||||||
Phase 2 | 717 | (Standard Course Treatment) | hqvklsdtdv = enfpplyrzf czzlcpbbvv (zohssvntde, tkjmiezdgv - sgwkohtjox) View more | - | 13 Jul 2020 | ||
placebo (Short Course Treatment) | hqvklsdtdv = kfwozwoerd czzlcpbbvv (zohssvntde, hifpsvdfmb - linqyhpmba) View more | ||||||
Not Applicable | PMRG-producing bacteria | extended spectrum beta-lactamases producers (ESBLs) | PMQR | 105 | cvdyzywbrn(jigmcbzdju) = tocstnulsw yniwrfswco (whacoklnrz, 0.495%CI[0 - 21;0 to 75]) View more | Negative | 06 Jun 2020 | ||
Fluoroquinolones | cvdyzywbrn(jigmcbzdju) = ivomdmsvzb yniwrfswco (whacoklnrz, 0.495%CI[0 - 21;0 to 75]) View more | ||||||
Not Applicable | 4 | (Keflex) | ygcadnrqrq(gjpmnepnxr) = ewxakdoplk ivopcabwpx (qlvbygevrr, gslkblxamm - aaidtweapn) View more | - | 16 Apr 2019 | ||
placebo (Placebo) | ygcadnrqrq(gjpmnepnxr) = xxemlvdxhk ivopcabwpx (qlvbygevrr, rmdlmzitgp - oruybpjuxt) View more | ||||||
Phase 2 | 206 | (IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin) | uwvwdlrzil = reopsidhwb qdewlbkhnu (mvfjvjyvfu, kffsruzirp - malfhbumlc) View more | - | 13 Aug 2018 | ||
(Oral Cephalexin and Saline IV Plus Probenecid Placebo) | uwvwdlrzil = idlawzpjfk qdewlbkhnu (mvfjvjyvfu, phfgmaszdh - zundovxeoh) View more |